—Mkt Cap: —P/E: —
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobr…
Industry Peers
Health Care Technologyloading…
Indicators:|
Key Statistics
Company
Market Cap—
Enterprise Value59.77M USD
Revenue (TTM)88.55M USD
Gross Profit67.14M USD
Net Income (TTM)-54.00M USD
Revenue/Share2.151 USD
Last Price—
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees296
CountryUS
SectorHealth Care
IndustryHealth Care Technology
ISINUS7458481014
Valuation
P/E (Trailing)—
P/E (Forward)-1.72
PEG—
EV/EBITDA-1.17
EV/Revenue0.67
P/S0.73
P/B1.42
EPS (TTM)-1.30
EPS (Forward)-0.89
52W Range
—
52W High—
52W Low—
Profitability
Gross Margin74.19%
Oper. Margin-62.94%
EBITDA Margin-57.78%
Profit Margin-59.67%
ROE-99.79%
ROA-41.77%
Growth
Revenue Growth-8.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-32.38M USD
CapEx (TTM)452.00K USD
FCF Margin-9.44%
FCF Yield—
Net Debt-5.28M USD
Net Debt/EBITDA0.10
Balance Sheet
Debt/Equity1.04
Current Ratio4.91
Quick Ratio3.85
Book Value/Sh1.083 USD
Cash/Share1.458 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.7 (Buy)
Target (Mean)5.167 USD
Target Range2.500 USD – 14.00 USD
# Analysts6
Ownership
Shares Out.42.24M
Float37.27M
Insiders4.66%
Institutions79.12%
Short Interest
Short Ratio9.6d
Short % Float10.00%
Short % Out.8.43%
Shares Short3.56M
Short (prev mo.)2.86M
Technical
SMA 501.360 USD
SMA 2001.669 USD
Beta0.18
S&P 52W Chg28.31%
Avg Vol (30d)—
Avg Vol (10d)484.35K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—